- Home
- SGML vs TYRA Comparison
SGML vs TYRA Comparison
Compare SGML & TYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGML
- TYRA
- Stock Information
- Founded
- SGML 2011
- TYRA 2018
- Country
- SGML Brazil
- TYRA United States
- Employees
- SGML N/A
- TYRA N/A
- Industry
- SGML Industrial Machinery/Components
- TYRA Biotechnology: Pharmaceutical Preparations
- Sector
- SGML Industrials
- TYRA Health Care
- Exchange
- SGML Nasdaq
- TYRA Nasdaq
- Market Cap
- SGML 518.6M
- TYRA 576.6M
- IPO Year
- SGML N/A
- TYRA 2021
- Fundamental
- Price
- SGML $5.44
- TYRA $10.47
- Analyst Decision
- SGML Strong Buy
- TYRA Strong Buy
- Analyst Count
- SGML 2
- TYRA 7
- Target Price
- SGML $18.00
- TYRA $30.86
- AVG Volume (30 Days)
- SGML 2.1M
- TYRA 364.1K
- Earning Date
- SGML 08-14-2025
- TYRA 08-06-2025
- Dividend Yield
- SGML N/A
- TYRA N/A
- EPS Growth
- SGML N/A
- TYRA N/A
- EPS
- SGML N/A
- TYRA N/A
- Revenue
- SGML $152,515,393.00
- TYRA N/A
- Revenue This Year
- SGML $43.73
- TYRA N/A
- Revenue Next Year
- SGML $130.53
- TYRA N/A
- P/E Ratio
- SGML N/A
- TYRA N/A
- Revenue Growth
- SGML 0.36
- TYRA N/A
- 52 Week Low
- SGML $4.25
- TYRA $6.42
- 52 Week High
- SGML $15.56
- TYRA $29.60
- Technical
- Relative Strength Index (RSI)
- SGML 52.92
- TYRA 58.12
- Support Level
- SGML $4.94
- TYRA $9.93
- Resistance Level
- SGML $5.95
- TYRA $10.49
- Average True Range (ATR)
- SGML 0.39
- TYRA 0.59
- MACD
- SGML 0.18
- TYRA 0.08
- Stochastic Oscillator
- SGML 70.00
- TYRA 94.30
About SGML Sigma Lithium Corporation
Sigma Lithium Corp together with its direct and indirect subsidiaries, is a commercial producer of lithium concentrate. It holds a 100% interest in four mineral properties: Grota do Cirilo, Sao Jose, Santa Clara, and Genipapo, located in the municipalities of Aracuai and Itinga, in the Vale do Jequitinhonha region in the State of Minas Gerais, Brazil.
About TYRA Tyra Biosciences Inc.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are TYRA-300, TYRA-200, and TYRA-430: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.